Skip to main content

TrAMPoline Pharma, Inc

  • | Biotech or pharma, therapeutic R&D
TrAMPoline Pharma, Inc

Following the recent approval of Iovance's Amtagvi®, now is the perfect time to invest in TrAMPoline Pharma, Inc (TPI). TPI is a phase 1 clinical stage biotech company developing novel synthetic co-receptors to enhance all forms of cellular immunotherapy. Our lead product consists of a genetically modified, autologous tumor-infiltrating lymphocyte (TIL)-based cell therapy (MightyTILTM) to address the high unmet need in solid cancers. In addition to MightyTIL we are also developing a universal TCR-T immunotherapeutic for hematologic malignancies and solid tumors that could also be used for allogeneic applications.

Address

Aurora
Colorado
United States
Visit website

Contact Exhibitor


Loading
View all Exhibitors
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors